WS-384

• Description :

  WS-384 is a dual LSD1 and DCN1-UBC12 protein-protein interaction inhibitor with oral activity, with IC50 values of 338.79 nM and 14.81 nM, respectively. WS-384 possesses anticancer activity and can cause cell cycle arrest, DNA damage, and induce apoptosis. WS-384 can be used in the research of non-small cell lung cancer (NSCLC) [1].

• UNSPSC :

  12352005

• Target :

  Apoptosis; Caspase; DNA/RNA Synthesis; E1/E2/E3 Enzyme; Histone Demethylase

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/ws-384.html

• Purity :

  98.23

• Solubility :

  DMSO : 17.86 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  BrC1=CC=C(CSC2=NN3C(SC4=NN=NN4CCN(C)C)=CC(C)=NC3=N2)C=C1.Cl

• Molecular Formula :

  C18H21BrClN9S2

• Molecular Weight :

  542.91

• References & Citations :

  [1]Li A, et al. Discovery of WS-384, a first-in-class dual LSD1 and DCN1-UBC12 protein-protein interaction inhibitor for the treatment of non-small cell lung cancer. Biomed Pharmacother. 2024;173:116240.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2247544-03-0]